361 Capital LLC purchased a new stake in Masimo Co. (NASDAQ:MASI) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,884 shares of the medical equipment provider’s stock, valued at approximately $675,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc grew its holdings in shares of Masimo by 2.7% during the third quarter. Vanguard Group Inc now owns 4,147,708 shares of the medical equipment provider’s stock worth $516,556,000 after buying an additional 109,065 shares during the last quarter. FMR LLC grew its holdings in shares of Masimo by 17.8% during the fourth quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock worth $417,622,000 after buying an additional 587,587 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd grew its holdings in shares of Masimo by 12.6% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 779,500 shares of the medical equipment provider’s stock worth $83,694,000 after buying an additional 87,476 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Masimo by 13.3% during the fourth quarter. Victory Capital Management Inc. now owns 726,329 shares of the medical equipment provider’s stock worth $77,986,000 after buying an additional 85,255 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Masimo by 11.7% during the first quarter. Janus Henderson Group PLC now owns 590,599 shares of the medical equipment provider’s stock worth $81,668,000 after buying an additional 61,762 shares during the last quarter. Institutional investors own 81.79% of the company’s stock.

A number of equities analysts recently issued reports on the company. UBS Group raised their price target on Masimo from $147.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Piper Jaffray Companies raised their price target on Masimo from $148.00 to $160.00 in a report on Friday, May 17th. Stifel Nicolaus raised their price target on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, May 17th. Needham & Company LLC reissued a “buy” rating and set a $158.00 price target (up previously from $155.00) on shares of Masimo in a report on Tuesday, May 7th. Finally, Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective on the stock in a report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $154.25.

Shares of MASI opened at $140.58 on Thursday. Masimo Co. has a twelve month low of $96.14 and a twelve month high of $147.91. The company has a market capitalization of $7.45 billion, a price-to-earnings ratio of 46.40, a price-to-earnings-growth ratio of 2.81 and a beta of 1.12.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The company had revenue of $231.70 million for the quarter, compared to analyst estimates of $223.67 million. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. As a group, equities research analysts forecast that Masimo Co. will post 3.12 earnings per share for the current fiscal year.

In other news, insider Jon Coleman sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $135.00, for a total transaction of $270,000.00. Following the sale, the insider now owns 13,201 shares of the company’s stock, valued at approximately $1,782,135. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ramshorst David J. Van sold 1,845 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $258,300.00. Following the sale, the chief accounting officer now directly owns 1,695 shares in the company, valued at approximately $237,300. The disclosure for this sale can be found here. Insiders sold a total of 45,572 shares of company stock worth $6,300,560 in the last ninety days. 11.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This article was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2019/05/23/361-capital-llc-takes-position-in-masimo-co-masi.html.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.